Gensight Biologics S.a annual debt-to-assets ratio
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a Debt-to-Assets Ratio Growth & History (SIGHT)
Gensight Biologics S.a's debt-to-assets ratio was 1.56 for fiscal 2025.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.56 | 0.87 | +125.24% |
| 2024 | 2024-12-31 | 0.69 | −0.33 | −32.06% |
| 2023 | 2023-12-31 | 1.02 | 0.90 | +752.20% |
| 2022 | 2022-12-31 | 0.12 | 0.08 | +201.17% |
| 2021 | 2021-12-31 | 0.04 | −0.02 | −27.88% |
| 2020 | 2020-12-31 | 0.06 | — | — |
Gensight Biologics S.a quarterly debt-to-assets ratio
Q4.24
Q4.25
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 1.56 | 0.22 | +16.27% |
| Q4 2024 | 2024-12-31 | 1.34 | — | — |
Gensight Biologics S.a debt-to-assets ratio trends
Over the last five fiscal years, Gensight Biologics S.a's debt-to-assets ratio increased from 0.06 to 1.56, a change of 1.50. The latest reported quarter, Q4 2025, shows 1.56.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...